文献速递结核与非结核分枝杆菌细菌感染、耐药与抗菌药物

GenoType NTM-DR试剂盒检测非结核分枝杆菌耐药性的评估

Evaluation of the new GenoType NTM-DR kit for the molecular detection of antimicrobial resistance in non-tuberculous mycobacteria.
PubMed 文献 · J Antimicrob Chemother · 2017-01-01

该研究评估了GenoType NTM-DR试剂盒在102株非结核分枝杆菌临床分离株中检测大环内酯类和氨基糖苷类耐药相关突变的表现,与Sanger测序符合率为98%(100/102),与表型药敏试验符合率为94.1%(96/102),表明该试剂盒能有效检测预测耐药性的突变。

要点

  • GenoType NTM-DR与测序结果符合率98%,可准确识别erm(41)基因型及rrl/rrs突变。
  • 与表型药敏符合率94.1%,4株克拉霉素耐药和2株阿米卡星耐药菌未检出突变。
  • 该试剂盒适用于鸟分枝杆菌复合群、脓肿分枝杆菌和龟分枝杆菌的耐药突变检测。

核心结论

  • GenoType NTM-DR试剂盒能有效检测鸟分枝杆菌复合群、脓肿分枝杆菌和龟分枝杆菌中预测大环内酯类和氨基糖苷类耐药的基因突变。

研究设计与样本

  • 评估102株非结核分枝杆菌分离株,包括参考株:16株鸟分枝杆菌、10株胞内分枝杆菌、8株奇美拉分枝杆菌、15株龟分枝杆菌和53株脓肿分枝杆菌(含18株erm(41) t28、10株c28的脓肿亚种、13株博莱蒂亚种和12株马赛亚种)。
  • 以erm(41)和rrl PCR测序及rrs 1400-1480区域测序为参考方法,表型以MIC微量稀释法确定。

主要发现

  • GenoType NTM-DR与Sanger测序结果在100/102(98%)分离株中一致。
  • 15株分离株(7株鸟分枝杆菌复合群、5株脓肿分枝杆菌、3株龟分枝杆菌)检出rrl突变(a2057c、a2058g、a2058t或a2059c),与获得性克拉霉素耐药相关。
  • 5株阿米卡星耐药分离株检出rrs突变a1408g。
  • 2株初始测序为野生型的分离株经NTM-DR检出rrl突变,重复测序确认。
  • 与表型药敏试验符合率为96/102(94.1%),4株克拉霉素耐药和2株阿米卡星耐药分离株未检出突变。

临床怎么用

  • 可用于快速检测NTM对克拉霉素和阿米卡星的耐药相关突变,辅助临床用药决策。
  • 对表型耐药但未检出突变的菌株,需结合表型药敏结果综合判断。

局限性

  • 未检出突变的耐药分离株可能导致假阴性,需依赖表型药敏补充。
  • 样本量有限,仅覆盖特定NTM物种。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Non-tuberculous mycobacteria (NTM) are emerging pathogens causing difficult-to-treat infections. We tested a new assay (GenoType NTM-DR) that detects natural and acquired resistance mechanisms to macrolides and aminoglycosides in frequently isolated NTM species. METHODS: Performance was assessed on 102 isolates including reference strains [16 Mycobacterium avium , 10 Mycobacterium intracellulare , 8 Mycobacterium chimaera , 15 Mycobacterium chelonae and 53 Mycobacterium abscessus (including subsp. abscessus isolates, 18 with a t28 in erm(41) and 10 with a c28, 13 subsp. bolletii isolates and 12 subsp. massiliense isolates)]. Genotypes were determined by PCR sequencing of erm(41) and rrl for clarithromycin resistance and of the 1400-1480 rrs region for aminoglycoside resistance. Phenotypes were determined by MIC microdilution. RESULTS: GenoType NTM-DR yielded results concordant with Sanger sequencing for 100/102 (98%) isolates. The erm(41) genotypic pattern was accurately identified for M. abscessus isolates . Mutations in rrl were detected in 15 isolates (7 M. avium complex, 5 M. abscessus and 3 M. chelonae ) with acquired clarithromycin resistance harbouring rrl mutations (a2057c, a2058g, a2058t or a2059c). Mutations in rrs were detected in five isolates with amikacin resistance harbouring the rrs mutation a1408g. In two isolates, the NTM-DR test revealed an rrl mutation (initial sequencing being WT), which was confirmed by re-sequencing. The test results were concordant with phenotypic susceptibility testing in 96/102 (94.1%) isolates, with four clarithromycin-resistant and two amikacin-resistant isolates not harbouring mutations. CONCLUSIONS: The GenoType NTM-DR test is efficient in detecting mutations predictive of antimicrobial resistance in M. avium complex, M. abscessus and M. chelonae.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Mougari F, Loiseau J, Veziris N, et al. Evaluation of the new GenoType NTM-DR kit for the molecular detection of antimicrobial resistance in non-tuberculous mycobacteria. J Antimicrob Chemother. 2017. PMID: 28333340. doi:10.1093/jac/dkx021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。